Is there known cases where a drug with equal efficacy but taken QD took over the market of a drug taken BID?
Truvada vs Combivir is close to such a case, although it’s hard to separate the enhanced convenience of qD dosing from the other advantages of Truvada. What we can say is that qD dosing certainly played a role in making Truvada (and later Atripla) the new SoC in the early lines of HIV treatment.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”